Physician

Daniel T. Milton, M.D.

According to 2025 Medicare claims, Daniel Milton, M.D. (NPI: 1205896818) practices hematology/oncology in the Indianapolis-Carmel-Greenwood, IN market, with the plurality of this provider's patient population coming from Hamilton, IN. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 46260-2082. Milton is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604) and Caravan Health ACO 50 LLC (ACO ID: A5160), participating under the MSSP model.

Milton's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 842 traditional Medicare patients, billed 69,152 HCPCS/CPT codes, and received $1,465,842 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,670 prescription claims across 330 beneficiaries totaling $6,609,153 in drug costs, led by Revlimid (Lenalidomide). DME data shows 38 claims. Open Payments data shows 53 records totaling $36,712. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,034,758 and ending at $1,465,842. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,260,877 to $6,609,153. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,422 to $1,234.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	718	134,597	$2,034,758
2016	705	120,055	$1,824,057
2017	874	105,399	$1,062,386
2018	831	69,309	$1,302,467
2019	867	67,187	$1,277,731
2020	921	75,730	$1,216,322
2021	897	86,978	$1,398,835
2022	927	120,164	$2,215,179
2023	985	114,733	$1,895,547
2024	842	69,152	$1,465,842

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	225	1,445	$2,260,877
2016	228	1,336	$2,360,933
2017	260	1,388	$2,183,163
2018	297	1,614	$2,867,867
2019	293	1,545	$2,817,209
2020	279	1,549	$2,853,066
2021	336	1,730	$4,039,641
2022	328	1,732	$4,773,685
2023	334	1,649	$4,841,622
2024	330	1,670	$6,609,153

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	25	199	$87,523
2016	N/R	108	$16,357
2017	N/R	11	$690
2018	N/R	55	$5,837
2019	N/R	56	$3,964
2020	N/R	88	$5,825
2021	24	152	$8,162
2022	N/R	118	$2,635
2023	N/R	46	$8,775
2024	N/R	38	$1,127

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	113	113	$153
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	349	735	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	505	669	$60
36415	Insertion of needle into vein for collection of blood sample	314	913	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	302	827	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	46	1,239	$846,532
Ojjaara	Momelotinib Dihydrochloride	21	630	$579,966
Jakafi	Ruxolitinib Phosphate	31	970	$534,795
Calquence	Acalabrutinib Maleate	32	960	$462,391
Erleada	Apalutamide	30	900	$439,579

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$476
E1392	Portable oxygen concentrator, rental	Y	N/R	11	$387
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$263

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	53	$36,712	Astellas Pharma US Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel T. Milton, M.D.?

Tedicare shows public-source Medicare data for Daniel T. Milton, M.D. (NPI 1205896818), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel T. Milton, M.D. have ACO affiliation data?

Daniel T. Milton, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604) and Caravan Health ACO 50 LLC (MSSP, ACO ID A5160).

What billing organization is linked to Daniel T. Milton, M.D.?

Daniel T. Milton, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Daniel T. Milton, M.D. have Open Payments data?

Daniel T. Milton, M.D. has 53 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.